[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622627":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":55,"id":58,"slug":26,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Zealand University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Placebo tablets + standard care",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention","ACTIVE_COMPARATOR","Cabergoline tablets + standard care",[19],"Drug: Cabergoline (Dopamine Agonist)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cabergoline (Dopamine Agonist)","This intervention will use cabergoline for antipsychotic induced hyperprolactinemia.",[15],null,{"type":22,"name":9,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo + standard care",[9],[31],{"name":32,"affiliation":5,"role":33},"Jesper Krogh","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Jesper Krogh, MD, PhD.","CONTACT","+45 25535485","jekrog@regionsjaelland.dk",[41],{"facility":5,"status":26,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":26},"Køge","Region Sjælland","4600","Denmark","DK",{"type":48,"coordinates":49},"Point",[50,51],12.18214,55.45802,{"lat":51,"lon":50},{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[56],{"name":57,"class":6},"Region Zealand","100622627",false,"NCT07386080","Carbergoline for Antipsychotic Induced Hyperprolactinemia.","The Safety of Carbergoline Versus Placebo for Antipsychotic Induced Hyperprolactinemia: A Pragmatic, Randomised, Non-inferiority Trial With Blinded Outcome.","Inclusion Criteria:\n\n* receiveing antipsychotic treatment for at least 3 months for a schizophrenia spectrum disorder\n* Prolactin levels \\> URL\n* symptoms of hyperprolactinemia according to he UKU side effect scale (Udvalg for Klinisk Undersøgelser)\n* no suicide ideation at time of recruitment (≤ 2 Columbia-Suicide Serverity Rating Scale)\n\nExclusion Criteria:\n\n* patients that has previously responded unfavorably to treatment with a dopamine receptor agonist.\n* The use of recreational drugs that may give hyperprolactinemia.","ALL","18 Years",{"count":67,"type":68},146,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer :\n\nIs the severity of positive and negative symptoms affected by the use of cabergoline?\n\nResearchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups.\n\nParticipants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.",[74],"Scizophrenia",[76,77],"prolactin","cabergoline","NOT_YET_RECRUITING","2026-01-27",{"date":81,"type":82},"2026-02-04","ACTUAL",{"date":84,"type":68},"2026-05-01",{"date":86,"type":68},"2029-05-01",{"name":5,"class":6},1]